Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07634016

Global Healthcare Study on Psoriasis

The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Psoriasis (PsO) Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

14 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed General Consent Form, or equivalent document
  • Confirmed diagnosis of Psoriasis

Exclusion criteria

  • Inability to provide informed consent.
  • Datasets with ambiguous or unclear diagnosis.

Treatment and study plan

Primary outcomes

  1. Psoriasis Area Severity Index (PASI)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Composite clinician-assessed measure of psoriasis severity based on erythema, scaling, thickness, and affected body surface area; total score ranges from 0 to 72, with higher scores indicating more severe disease.

Secondary outcomes

  1. Dermatology Life Quality Index (DLQI)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.

  2. Nail Psoriasis Severity Index (NAPSI)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Clinician-assessed measure of nail psoriasis severity based on nail matrix and nail bed involvement; scores range from 0-80 for fingernails and 0-80 for toenails; total score ranges from 0-160, with higher scores indicating more severe nail disease.

  3. Numerical Rating Scale (NRS) for disease severity

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Patient-reported assessment of psoriasis severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable).

  4. Physician Global Assessment (PGA)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Clinician-assessed global measure of psoriasis severity on a scale from 0 (clear) to 4 (severe).

  5. Body Surface Area (BSA)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Percentage of total body surface area affected by psoriasis, ranging from 0% to 100%.

Study contacts

Contact information is provided by the study sponsor or research team.

Johannes A Didaskalu, Prof. Dr. med.

CONTACT

[email protected]

+41 76 36 19 475

Julia-Tatjana Maul

CONTACT

[email protected]

+41 76 441 51 09

Sponsors and collaborators

Lead sponsor

Julia Tatjana Maul

Other

Collaborators

  • University Hospital, Zürich
  • University of Zurich

Registry information

Acronym: GHSP

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Jun 8, 2026
Registry last updated
Jun 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.